Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given Consensus Rating of “Strong Buy” by Brokerages
Shares of Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price target of $10.00 for the company and are predicting that the company will post ($0.01) EPS for the current quarter, according to Zacks. Zacks has also given Kitov Pharmaceuticals an industry rank of 158 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright raised Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Tuesday, November 21st.
Kitov Pharmaceuticals Company Profile
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.